A risk for physical drug incompatibilities when the patient has a saline lock is reduced when.

A. increased risk for speed shock: IV push medications enter the bloodstream rapidly, creating a high risk for speed shock, which is a toxic reaction caused by sudden drug administration. Symptoms may include dizziness, hypotension, irregular pulse, and cardiovascular collapse if not controlled.

B. increased risk for infiltration: Infiltration occurs when IV fluid or medication leaks into surrounding tissue. While possible with any IV therapy, it is not uniquely associated with IV push administration, since the risk is higher with prolonged infusions.

C. increased risk for infection: Infection risk is present with all IV routes due to potential contamination, but IV push does not specifically increase this risk compared to other IV methods when proper aseptic technique is followed.

D. a slow drug response: IV push produces one of the fastest drug responses because the medication is delivered directly into circulation. This makes it the opposite of a slow response, which is more characteristic of oral routes.

A. Start a new IV access to avoid compatibility issues with the new antibiotic: A new IV site is not always necessary unless incompatibility is confirmed. Starting a new IV without assessing compatibility would expose the patient to unnecessary discomfort and risk of complications.

B. Start a new IV access to avoid too much volume at one IV site: The volume infused at one IV site is generally well tolerated if the line is patent. Adding a piggyback antibiotic does not usually cause excessive volume at the site.

C. Increase the continuous infusion to facilitate administration of the antibiotic: Increasing the rate of continuous infusion is unsafe because it alters the prescribed fluid balance. This could put the patient at risk for fluid overload or disrupt carefully ordered fluid therapy.

D. Check if the antibiotic is compatible with the continuous infusion solution: This is the safest action because some drugs may precipitate or inactivate when combined in the same line. Verifying compatibility ensures that the antibiotic can be administered through the existing IV line without compromising safety or effectiveness.